SAB Biotherapeutics (SABS) Earnings Date, Estimates & Call Transcripts $2.20 -0.03 (-1.35%) Closing price 04:00 PM EasternExtended Trading$2.20 0.00 (0.00%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SAB Biotherapeutics Earnings Summary SAB Biotherapeutics issued Q2 2025 earnings on August 7, 2025, reporting an EPS of -$1.09, which missed analysts' consensus estimates of -$0.82 by $0.27. With a trailing EPS of -$3.70, SAB Biotherapeutics' earnings are expected to grow next year, from ($3.69) to ($2.98) per share. Latest Q2 Earnings DateAug. 7EstimatedConsensus EPS (Aug. 7) -$0.82 Actual EPS (Aug. 7) -$1.09 Missed By -$0.27 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)Powered by Get SAB Biotherapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSABS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SABS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. SAB Biotherapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$1.14-$1.14-$1.14Q2 20252-$1.10-$0.58-$0.84Q3 20252-$0.43-$0.07-$0.25Q4 20252-$0.42-$0.06-$0.24 SAB Biotherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025-$0.82-$1.09 -$0.27-$1.09$0.10M-5/9/2025Q1 2025-$1.00-$0.56+$0.44-$0.56$0.13M-3/28/2025Q4 2024-$1.16-$1.23 -$0.07-$1.23$0.12M$0.05M11/6/2024--$1.07-$1.12 -$0.05-$1.12$0.50M-8/8/2024--$1.13-$0.79+$0.34-$0.79-$0.26M5/20/2024Q1 2024-$0.98-$0.54+$0.44-$0.54-$0.95M11/13/2023Q3 2023-$0.10-$0.10--$0.10-$1.27M8/21/2023Q2 2023-$0.14-$0.14--$0.14-$0.09M SAB Biotherapeutics Earnings - Frequently Asked Questions When did SAB Biotherapeutics announce their last quarterly earnings? SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earning data on Thursday, August 7, 2025. Learn more on SABS's earnings history. Did SAB Biotherapeutics beat their earnings estimates last quarter? In the previous quarter, SAB Biotherapeutics (NASDAQ:SABS) missed the analysts' consensus estimate of ($0.82) by $0.27 with a reported earnings per share (EPS) of ($1.09). Learn more on analysts' earnings estimate vs. SABS's actual earnings. How much profit does SAB Biotherapeutics generate each year? SAB Biotherapeutics (NASDAQ:SABS) has a recorded net income of -$34.10 million. SABS has generated -$3.70 earnings per share over the last four quarters. What is SAB Biotherapeutics' EPS forecast for next year? SAB Biotherapeutics' earnings are expected to grow from ($3.69) per share to ($2.98) per share in the next year. More Earnings Resources from MarketBeat Related Companies Achieve Life Sciences Earnings Dominari Earnings Fortress Biotech Earnings Curis Earnings Bolt Biotherapeutics Earnings Amgen Earnings Gilead Sciences Earnings Vertex Pharmaceuticals Earnings Regeneron Pharmaceuticals Earnings Alnylam Pharmaceuticals Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Dutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a RallyRivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline This page (NASDAQ:SABS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
